AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fass, R J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fass, R J

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1993 November; 37(11): 2348-2357

In vitro activity of Bay y 3118, a new quinolone.

R J Fass

Department of Internal Medicine, Ohio State University College of Medicine, Columbus 43210.

ABSTRACT

MICs of Bay y 3118, ciprofloxacin, ofloxacin, clarithromycin, azithromycin, cefuroxime, amoxicillin-clavulanate, and trimethoprim-sulfamethoxazole for 878 recent clinical isolates were determined by broth microdilution methods. Among the three quinolones, Bay y 3118 was the most active against Haemophilus influenzae, Moraxella catarrhalis, Acinetobacter baumannii, Xanthomonas maltophilia, gram-positive cocci, and anaerobes; MICs for 50% of the strains (MIC50s) and MIC90s were < or = 0.015 and < or = 0.015, < or = 0.015 and < or = 0.015, 0.03 and 2, 0.25 and 0.5, 0.06 and 1, and 0.12 and 0.25 micrograms/ml, respectively. For gram-positive cocci and anaerobes, these values were 16- to 32-fold (4 to 5 log2 dilution steps) lower than those for ciprofloxacin and ofloxacin. Bay y 3118 was similar in activity to ciprofloxacin and more active than ofloxacin against members of the family Enterobacteriaceae and Pseudomonas aeruginosa; Bay y 3118 MIC50s and MIC90s were 0.03 and 0.25 and 0.5 and 8 micrograms/ml, respectively. Scattergrams and regression analyses comparing quinolone MICs indicated that, despite differences in activity, organisms relatively susceptible to one were relatively susceptible to all and organisms relatively resistant to one were relatively resistant to all. However, the greater in vitro activity of Bay y 3118 was most pronounced against relatively resistant organisms. Pending pharmacokinetic and safety data for Bay y 3118, there is reasonable anticipation that its enhanced activity against gram-positive cocci and anaerobes would broaden the clinical utility of the quinolone class of antimicrobial agents.


Antimicrob Agents Chemother. 1993 November; 37(11): 2348-2357




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 1993 by the American Society for Microbiology. All rights reserved.